Nautilus Biotechnology Financials - Benzinga

Nautilus Biotechnology Inc

NAUTNASDAQ

Trade with Public

Trade with Public

$1.36

0.2522.97%

가까이에: Sep 29, 5:00 PM EST

$1.52

0.1611.36%

시간외: 7:54 PM EST

PRO

변동 이유?:Nautilus Biotechnology shares are trading higher after Roth Capital initiat...

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Nautilus Biotechnology Financials

Nautilus Biotechnology (NAUT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Nautilus Biotechnology Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $190.000K

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 8.33 percent increase over losses of $(0.12) per share

Benzinga Newsdesk

Earnings Scheduled For April 28, 2026

Benzinga Insights

PRO
Nautilus Biotechnology Q1 EPS $(0.12) Beats $(0.17) Estimate

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 25 percent. This is a 7.69 percent increase over losses of $(0.13) per share

Benzinga Newsdesk

PRO
Nautilus Does Not Anticipate Material Revenue In 2026 From Early Access Program Engagement

Benzinga Newsdesk

PRO
Nautilus Biotechnology Q4 EPS $(0.11) Beats $(0.14) Estimate

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 21.43 percent increase over losses of $(0.14) per share

Benzinga Newsdesk

Earnings Scheduled For October 28, 2025

Benzinga Insights

© 2026 Benzinga | All Rights Reserved